Thank you for the question.
For commercialization, we actually have a separate arm of TRIUMF called TRIUMF Innovations. The intent of TRIUMF Innovations is to look into TRIUMF and identify any IP that can be spun out or commercialized in work with both our researchers and external groups to try to develop new approaches or techniques that can be put to market.
Medical isotopes are certainly one area in which that's very active at the moment. We are beginning to develop commercialization links with several groups, but we do have a group actually located in TRIUMF, called BWXT, which runs a suite of cyclotrons that are used for isotope development. We are basically generating income either from royalties or from some of the operational aspects as BWXT creates these isotopes and they go as far abroad as UBC and Australia, so there's a very broad set of destinations for those products.
I would note that somewhere between 10% and 15% of the commercialization income—we have about a $90-million to $100-million operational cost per year—is derived from those commercial operations. But we would certainly note that commercialization is just one of the benefits that we can create. The societal benefit from being able to create these isotopes and hopefully cure cancers and certainly use them for diagnostics is one of the big societal benefits that we can introduce. So there is not just the commercialization and the income creation but also the impact of the technologies and the techniques that are being developed here.